Funding for this research was provided by:
FP7 Health (602570)
Received: 10 August 2017
Accepted: 6 May 2019
First Online: 17 June 2019
Change Date: 13 December 2019
Change Type: Correction
Change Details: Following publication of the original article , we have been notified that end note would need to be adjusted.
: Not provided.
: Ethics approval has been obtained from:The Netherlands: CCMO (leading Ethical Committee) NL57593.000.16 dd. 6 February 2017MEC of Erasmus MC: dossier ABR: NL57593.000.16 dd. 15 March 2017Belgium: Leading Ethical Committee UZ Brussels 2016/316 dd. 22 February 2017Spain: CEIm, Hospital Clinic Barcelona, 25/2016 dd. 23 December 2016Participants provide written informed consent before screening. Participants have the opportunity to review written consent with the investigator, ask questions and clarification. An optional two week consideration period is offered.
: Not applicable.
: CB and BM are co-inventors of the HTI immunogen sequence. CB is CSO of, and receives compensation from, AELIX Therapeutics, a Barcelona biotech company developing HTI in the context of different vaccine vectors. BM is a consultant for AELIX Therapeutics. KT is the founder and SCO of eTheRNA and receives compensation from eTheRNA, a Brussels immunotherapy spin-off company of Vrije Universiteit Brussel. All other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.